Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$167K Buy
+12,595
New +$200K ﹤0.01% 850
2022
Q4
Sell
-230,043
Closed -$2.75M 1034
2022
Q3
$2.75M Buy
230,043
+12,600
+6% +$271K 0.02% 666
2022
Q2
$6.9M Buy
217,443
+36,100
+20% +$928K 0.04% 516
2022
Q1
$5M Buy
181,343
+1,600
+0.9% +$56.8K 0.03% 596
2021
Q4
$9.05M Buy
179,743
+40,881
+29% +$1.84M 0.04% 427
2021
Q3
$4.93M Buy
138,862
+42,130
+44% +$1.67M 0.02% 584
2021
Q2
$4.3M Buy
96,732
+42,900
+80% +$1.46M 0.02% 634
2021
Q1
$1.97M Sell
53,832
-1,400
-3% -$58.2K 0.01% 699
2020
Q4
$2.37M Buy
55,232
+20,212
+58% +$742K 0.01% 649
2020
Q3
$703K Buy
+35,020
New +$685K ﹤0.01% 870

Other funds holding XPEV

Aviva's XPEV Position: Q2 2026 in Review

Aviva opened a new position in XPeng (XPEV) in Q2 2026: 12,595 shares worth $167K. The stake represents ﹤0.01% of the portfolio and ranks #850 among its holdings. This is a return to the name: Aviva previously reported a position in XPEV as recently as Q3 2022.

Aviva first reported a position in XPEV in Q3 2020 and has held it in 10 quarters since. The position peaked at $9.05M in Q4 2021. 220 funds tracked by Wall St. Rank hold XPEV as of Q2 2026.

  • Aviva held 12,595 shares of XPeng worth $167K as of Q2 2026.
  • XPeng was a new Aviva position in Q2 2026.
  • XPeng made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #850 holding.
  • Aviva first reported a position in XPeng in Q3 2020 and has held it in 10 quarters since.
  • Aviva's XPeng position peaked at $9.05M in Q4 2021.
  • 220 funds tracked by Wall St. Rank held XPeng as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.